# TRANSFORMING PROMISING MOLECULES INTO VALUED MEDICINES – THE EMERGING ALDERLEY PARK TRANSLATIONAL SCIENCE ECOSYSTEM (APTRANS)

Paul Holme<sup>1</sup>, Richard Knight<sup>2</sup>, Jonathan Lewis<sup>3</sup>, Robert Clay<sup>4</sup>, Ned Wakeman<sup>5</sup>, Paul A Dickinson<sup>6</sup>, Marcel de Matas<sup>6</sup>

APTrans@sedapds.com

<sup>1</sup>Alderley Analytical, <sup>2</sup>Apconix, <sup>3</sup>Aptus Clinical, <sup>4</sup>Highbury Regulatory Science, <sup>5</sup>The BioHub at Alderley Park, <sup>6</sup>SEDA Pharmaceutical Development Services<sup>®</sup>

The BioHub at Alderley Park, Alderley Edge, Cheshire, SK10 4TG



### Outline

- The APTrans Vision
- APTrans Business Drivers
- APTrans The Translational Science Ecosystem
- The APTrans Differential Advantage
- APTrans in the Heart of England's North West

#### Transforming Promising Molecules into Valued Medicines



# APTrans exists to promote the rapid translation of promising science and exciting medical discoveries into valued medicinal products


Published online 11 June 2008 | *Nature* **453**, 840-842 (2008) | doi:10.1038/453840a

#### News Feature

# Translational research: Crossing the valley of death

A chasm has opened up between biomedical researchers and the patients who need their discoveries. Declan Butler asks how the ground shifted and whether the US National Institutes of Health can bridge the gap.

Declan Butler





#### **APTrans Business Drivers**

- Increasing drivers for newer and better medicines (global megatrends)
- Increasing barriers to approval and reimbursement of new medicines
- Increasing incentives from health agencies to accelerate drug development
- Increasing externalisation activity in big pharma
- Improving environment for investment
- Growth of Biotech Industry and Specialist Discovery Organisations
- Great basic science in academia
  - spin outs



# The Alderley Park Translational Science Ecosystem Transforming Promising Molecules into Valued Medicines



#### **APTrans Core Skills**

- An informal association of companies providing the expertise required for drug development consultancy and delivery:
  - Safety Assessment / Preclinical Toxicity
  - CMC (drug substance and drug product)
  - Clinical Pharmacology / Pharmacokinetics
  - Clinical Trial design and delivery
  - Regulatory guidance
  - Discovery and Regulatory Bioanalysis
  - Business Opportunity Assessment and Due Diligence
- Experience across most therapy areas with particular expertise in Oncology









## The APTrans Differential Advantage

- Advantages of APTrans include:
  - Track record of delivering products to market
  - Long-standing experience across a broad range of disease and therapy areas at all stages of development
  - Individuals across the spectrum of disciplines with an outstanding track record of contributing to regulatory science and influencing regulatory guidance.
  - Fully integrated drug development advice and services in a 'one-stop shop'
  - Excellent connections to high-profile, academic centres of excellence, globally leading hospitals, innovative technology businesses and specialist contract research organisations

#### TRANSFORMING PROMISING MOLECULES INTO VALUED MEDICINES



## APTrans in the Heart of England's North West

### World's largest early clinical trials unit opens at The Christie in Manchester

Press Release Posted 22 November 2010

#### Phase 1 trials and chemotherapy unit open in new £35 million centre

· See accompanying fact sheet about clinical trials and research at The Christie.

The cancer centre The Christie in Manchester, already leading across the globe for its research, today opens the world's largest early clinical trials unit

It is housed in a newly completed £35 million three storey building at its main site and also includes the biggest chemotherapy facility in the UK and The Christie Clinic private patients' suite to boost its income. It is hoped the new unit will help develop new treatments for a whole range of cancers and save lives across the globe.



Phase 1 trials and chemotherapy unit open in new £35 million centre

2,400 patients a year will be able to access the latest treatments through the clinical trials, with around 200 drug trials going on at any one time.

http://www.christie.nhs.uk/about-the-christie/latest-news/2010/221110.aspx

#### AstraZeneca and University form North West Centre for Advanced Drug Delivery

30 October 2014

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients.

The North West Centre for Advanced Drug Delivery will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the University.

http://blogs.mhs.manchester.ac.uk/news-hub/2014/10/30/astrazeneca-and-university-form-north-west-centre-for-advanced-drug-delivery/

#### AstraZeneca, GSK and The University of Manchester Set Up Centre for Inflammation Research







Pial Ganguli

http://www.pharma-share.com/astrazeneca-gsk-university-manchester-set-centre-inflammation-research

